[{"address1": "22 Boston Wharf Road", "address2": "10th floor", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "617 349 1971", "fax": "617 273 2637", "website": "https://www.astriatx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 78, "companyOfficers": [{"maxAge": 1, "name": "Ms. Jill C. Milne Ph.D.", "age": 57, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 967338, "exercisedValue": 0, "unexercisedValue": 335644}, {"maxAge": 1, "name": "Mr. Benjamin S. Harshbarger J.D.", "age": 56, "title": "Chief Legal Officer", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 658041, "exercisedValue": 0, "unexercisedValue": 94668}, {"maxAge": 1, "name": "Dr. Christopher J. Morabito M.D.", "age": 55, "title": "Chief Medical Officer", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 690824, "exercisedValue": 0, "unexercisedValue": 204914}, {"maxAge": 1, "name": "Mr. Noah C. Clauser CPA", "age": 52, "title": "CFO & Treasurer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 621406, "exercisedValue": 0, "unexercisedValue": 29493}, {"maxAge": 1, "name": "Ms. Keri  McGrail", "title": "Chief Human Resources Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Andrea L. Matthews", "age": 43, "title": "Chief Business Officer", "yearBorn": 1982, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew A. Komjathy", "age": 62, "title": "Chief Commercial Officer", "yearBorn": 1963, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Ruesch", "title": "Senior Vice President of Pharmaceutical Sciences & Technical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rafif  Dagher", "title": "Senior VP and Head of Discovery, Nonclinical Development & Translational Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1768176000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 12.58, "open": 12.48, "dayLow": 12.45, "dayHigh": 12.59, "regularMarketPreviousClose": 12.58, "regularMarketOpen": 12.48, "regularMarketDayLow": 12.45, "regularMarketDayHigh": 12.59, "payoutRatio": 0.0, "beta": 0.019, "forwardPE": -5.2562747, "volume": 3057633, "regularMarketVolume": 3057633, "averageVolume": 1082931, "averageVolume10days": 1080590, "averageDailyVolume10Day": 1080590, "bid": 8.95, "ask": 16.0, "bidSize": 2, "askSize": 2, "marketCap": 718127296, "fiftyTwoWeekLow": 3.555, "fiftyTwoWeekHigh": 13.29, "allTimeHigh": 1017.6, "allTimeLow": 2.36, "priceToSalesTrailing12Months": 1017.1775, "fiftyDayAverage": 12.7452, "twoHundredDayAverage": 8.27805, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 590189248, "profitMargins": 0.0, "floatShares": 38901605, "sharesOutstanding": 57084838, "sharesShort": 5752164, "sharesShortPriorMonth": 4813071, "sharesShortPreviousMonthDate": 1764288000, "dateShortInterest": 1767139200, "sharesPercentSharesOut": 0.1008, "heldPercentInsiders": 0.00481, "heldPercentInstitutions": 0.949, "shortRatio": 4.7, "shortPercentOfFloat": 0.1265, "impliedSharesOutstanding": 57084838, "bookValue": 2.444, "priceToBook": 5.1472993, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -124030000, "trailingEps": -2.14, "forwardEps": -2.39333, "lastSplitFactor": "1:6", "lastSplitDate": 1629417600, "enterpriseToRevenue": 835.962, "52WeekChange": 0.668435, "SandP52WeekChange": 0.14987159, "quoteType": "EQUITY", "currentPrice": 12.58, "targetHighPrice": 49.0, "targetLowPrice": 13.0, "targetMeanPrice": 24.6, "targetMedianPrice": 13.0, "recommendationMean": 2.71429, "recommendationKey": "hold", "numberOfAnalystOpinions": 5, "totalCash": 227720992, "totalCashPerShare": 3.989, "totalDebt": 4459000, "quickRatio": 10.416, "currentRatio": 10.781, "totalRevenue": 706000, "debtToEquity": 1.912, "revenuePerShare": 0.012, "returnOnAssets": -0.26935, "returnOnEquity": -0.43148, "grossProfits": 706000, "freeCashflow": -80486752, "operatingCashflow": -119733000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -48.305954, "financialCurrency": "USD", "symbol": "ATXS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "priceEpsCurrentYear": -5.797235, "fiftyDayAverageChange": -0.16520023, "regularMarketDayRange": "12.45 - 12.59", "fullExchangeName": "NasdaqGM", "epsTrailingTwelveMonths": -2.14, "epsForward": -2.39333, "epsCurrentYear": -2.17, "fiftyDayAverageChangePercent": -0.01296176, "twoHundredDayAverageChange": 4.3019495, "twoHundredDayAverageChangePercent": 0.51968145, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Catabasis Pharmaceuticals, Inc.", "nameChangeDate": "2026-01-23", "averageAnalystRating": "2.7 - Hold", "dividendDate": 1546214400, "earningsTimestamp": 1762954200, "earningsTimestampStart": 1762954200, "earningsTimestampEnd": 1762954200, "isEarningsDateEstimate": false, "averageDailyVolume3Month": 1082931, "fiftyTwoWeekLowChange": 9.025, "fiftyTwoWeekLowChangePercent": 2.5386777, "fiftyTwoWeekRange": "3.555 - 13.29", "fiftyTwoWeekHighChange": -0.71000004, "fiftyTwoWeekHighChangePercent": -0.05342363, "fiftyTwoWeekChangePercent": 66.8435, "regularMarketChange": 0.0, "cryptoTradeable": false, "exchange": "NGM", "messageBoardId": "finmb_100802824", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "corporateActions": [{"header": "Delisting", "message": "ATXS is being delisted effective Jan. 26, 2026", "meta": {"eventType": "DELISTING", "dateEpochMs": 1769403600000}}], "regularMarketTime": 1769115601, "shortName": "Astria Therapeutics, Inc.", "longName": "Astria Therapeutics, Inc.", "marketState": "CLOSED", "regularMarketChangePercent": 0.0, "regularMarketPrice": 12.58, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1435239000000, "displayName": "Astria Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-01-24"}]